603392 万泰生物
午间休市 07-24 11:29:57
资讯
新帖
简况
以诊断创新赋能全球健康万泰生物亮相吉隆坡WHX Labs 2025
动脉网 · 01:01
以诊断创新赋能全球健康万泰生物亮相吉隆坡WHX Labs 2025
7月23日万泰生物现1198.6万元大宗交易
证券之星 · 07-23 09:23
7月23日万泰生物现1198.6万元大宗交易
万泰生物获融资买入0.18亿元,近三日累计买入0.53亿元
金融界 · 07-19
万泰生物获融资买入0.18亿元,近三日累计买入0.53亿元
万泰生物中标23.72万元 金额占比小对业绩影响有限
自选股中标信息 · 07-18
万泰生物中标23.72万元 金额占比小对业绩影响有限
万泰生物中标1.10万元 金额较小对业绩影响有限
自选股中标信息 · 07-18
万泰生物中标1.10万元 金额较小对业绩影响有限
生物疫苗概念盘中跳水,万泰生物跌0.18%
市场透视 · 07-18
生物疫苗概念盘中跳水,万泰生物跌0.18%
万泰生物:九价HPV疫苗市场定价为499元/支
证券之星 · 07-16
万泰生物:九价HPV疫苗市场定价为499元/支
万泰生物:公司将全力以赴做好研发和经营工作
互动易 · 07-16
万泰生物:公司将全力以赴做好研发和经营工作
万泰生物:中标北京市红十字血液中心采购项目,中标金额为104.58万元
同壁财经 · 07-15
万泰生物:中标北京市红十字血液中心采购项目,中标金额为104.58万元
幽门螺杆菌概念盘中跳水,*ST三圣跌0.20%
市场透视 · 07-15
幽门螺杆菌概念盘中跳水,*ST三圣跌0.20%
生物制品行业盘中跳水,万泰生物跌0.14%
市场透视 · 07-15
生物制品行业盘中跳水,万泰生物跌0.14%
每周股票复盘:万泰生物(603392)九价HPV疫苗销售策略及海外拓展
证券之星 · 07-12
每周股票复盘:万泰生物(603392)九价HPV疫苗销售策略及海外拓展
巨头争相入局 竞逐千亿级医美赛道
中国产业经济信... · 07-12
巨头争相入局 竞逐千亿级医美赛道
万泰生物举办资本市场专项调研会
新华网 · 07-10
万泰生物举办资本市场专项调研会
打破高价壁垒!国产九价HPV疫苗499元上市,98%保护率+两针法(9-17岁)成亮点
金融界 · 07-10
打破高价壁垒!国产九价HPV疫苗499元上市,98%保护率+两针法(9-17岁)成亮点
定价499元,大打“低价牌”万泰生物为何没能赢得市场的心?
大众证券报 · 07-09
定价499元,大打“低价牌”万泰生物为何没能赢得市场的心?
2025年中国疫苗产业格局重构:九价HPV疫苗市场突破与全产业链升级分析
报告大厅 · 07-09
2025年中国疫苗产业格局重构:九价HPV疫苗市场突破与全产业链升级分析
万泰生物:7月8日接受机构调研,东方基金、红土创新基金等多家机构参与
证星公司调研 · 07-08
万泰生物:7月8日接受机构调研,东方基金、红土创新基金等多家机构参与
国产九价HPV疫苗与进口效果相当,最终定价仅499元,不到进口一半
新华网 · 07-08
国产九价HPV疫苗与进口效果相当,最终定价仅499元,不到进口一半
万泰生物:公司正在全力推进九价HPV疫苗WHO PQ认证进程
蓝鲸财经 · 07-08
万泰生物:公司正在全力推进九价HPV疫苗WHO PQ认证进程
加载更多
公司概况
公司名称:
北京万泰生物药业股份有限公司
所属行业:
医药制造业
上市日期:
2020-04-29
主营业务:
北京万泰生物药业股份有限公司的主营业务是体外诊断试剂、自动化检测设备、疫苗研发生产及销售。公司的主要产品是公司业务不断向多元化拓展,目前已形成了包括原料、质控品、诊断设备、免疫、生化、分子、疫苗在内的全产业链医防融合产品布局,横跨七个不同的技术平台。截至报告期末,体外诊断领域,公司拥有有效专利167项,其中发明专利117项,实用新型专利43项,外观设计7项。报告期内,公司申请专利52项,其中发明专利39项;获得授权专利26项,其中国内授权21项,国际授权5项。
发行价格:
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":60.27,"timestamp":1753327797000,"preClose":59.93,"halted":0,"volume":2627144,"delay":0,"changeRate":0.0057,"floatShares":1265000000,"shares":1265000000,"eps":-0.0572,"marketStatus":"午间休市","change":0.34,"latestTime":"07-24 11:29:57","open":59.93,"high":60.46,"low":59.83,"amount":158000000,"amplitude":0.0105,"askPrice":60.28,"askSize":37,"bidPrice":60.27,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.0572,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753333200000},"marketStatusCode":3,"adr":0,"adjPreClose":59.93,"symbolType":"stock","openAndCloseTimeList":[[1753320600000,1753327800000],[1753333200000,1753340400000]],"highLimit":65.92,"lowLimit":53.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1265122774,"isCdr":false,"pbRate":6.21,"roa":"--","roe":"--","epsLYR":0.08,"committee":-0.624309,"marketValue":76249000000,"turnoverRate":0.0021,"status":0,"floatMarketCap":76249000000},"requestUrl":"/m/hq/s/603392","defaultTab":"news","newsList":[{"id":"2553224931","title":"以诊断创新赋能全球健康万泰生物亮相吉隆坡WHX Labs 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553224931","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553224931?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:01","pubTimestamp":1753318860,"startTime":"0","endTime":"0","summary":"万泰生物在吉隆坡WHX Labs 2025展会上展示其前沿诊断创新方案,包括化学发光、酶联免疫、胶体金等平台,吸引国际关注,并与东南亚医疗机构探讨合作,助力全球健康事业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724093625954fc016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724093625954fc016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603392","BK0239"],"gpt_icon":0},{"id":"2553159215","title":"7月23日万泰生物现1198.6万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2553159215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553159215?lang=zh_cn&edition=full","pubTime":"2025-07-23 17:23","pubTimestamp":1753262598,"startTime":"0","endTime":"0","summary":"证券之星消息,7月23日万泰生物发生大宗交易,交易数据如下:大宗交易成交价格59.93元,成交20万股,成交金额1198.6万元,买方营业部为国金证券股份有限公司厦门湖滨南路证券营业部,卖方营业部为国金证券股份有限公司深圳分公司。近三个月该股共发生3笔大宗交易,合计成交1.02万手。截至2025年7月23日收盘,万泰生物报收于59.93元,上涨0.69%,换手率0.36%,成交量4.54万手,成交额2.71亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072300029254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK0239","LU1981816686.USD","BK1200","09633","BK1589"],"gpt_icon":0},{"id":"2552413134","title":"万泰生物获融资买入0.18亿元,近三日累计买入0.53亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552413134","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552413134?lang=zh_cn&edition=full","pubTime":"2025-07-19 08:02","pubTimestamp":1752883357,"startTime":"0","endTime":"0","summary":"7月18日,沪深两融数据显示,万泰生物获融资买入额0.18亿元,居两市第814位,当日融资偿还额0.26亿元,净卖出833.12万元。最近三个交易日,16日-18日,万泰生物分别获融资买入0.13亿元、0.22亿元、0.18亿元。融券方面,当日融券卖出0.38万股,净卖出0.38万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071908173897abaf3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071908173897abaf3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2552461156","title":"万泰生物中标23.72万元 金额占比小对业绩影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2552461156","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552461156?lang=zh_cn&edition=full","pubTime":"2025-07-18 18:21","pubTimestamp":1752834100,"startTime":"0","endTime":"0","summary":"2025年07月18日,据天眼查数据,邢台市中心血站酶免试剂采购项目F包补充合同显示,中标方为万泰生物,招标方为邢台市中心血站,金额23.72万元。财务影响方面,可参考公司2024年营收总额22.45亿元,本次中标金额占比较少。近半年内,万泰生物获得1家券商积极评价:国投证券给予\"增持\"评级。万泰生物主营业务涵盖试剂,疫苗,代理产品,其他收入之和。截至发稿,万泰生物股价报60.02元,上涨0.18%,成交额至2.13亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718182144a6b1f32c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718182144a6b1f32c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2552461153","title":"万泰生物中标1.10万元 金额较小对业绩影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2552461153","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552461153?lang=zh_cn&edition=full","pubTime":"2025-07-18 18:21","pubTimestamp":1752834090,"startTime":"0","endTime":"0","summary":"2025年07月18日,据天眼查数据,邢台市中心血站酶免试剂采购项目H包补充合同显示,中标方为万泰生物,招标方为邢台市中心血站,金额1.10万元。财务影响方面,可参考公司2024年营收总额22.45亿元,本次中标金额占比较少。近半年内,万泰生物获得1家券商积极评价:国投证券给予\"增持\"评级。万泰生物主营业务涵盖试剂,疫苗,代理产品,其他收入之和。截至发稿,万泰生物股价报60.02元,上涨0.18%,成交额至2.13亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718182133a453487a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718182133a453487a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2552453630","title":"生物疫苗概念盘中跳水,万泰生物跌0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552453630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552453630?lang=zh_cn&edition=full","pubTime":"2025-07-18 09:48","pubTimestamp":1752803308,"startTime":"0","endTime":"0","summary":"07月18日,生物疫苗概念盘中跳水,截至09点48分,生物疫苗概念整体指数下跌1.02%,报2364.950点。从个股上来看,该概念的成分股中,万泰生物跌0.18%,天康生物、博雅生物、白云山跌幅居前。从资金上来看,截止发稿,生物疫苗概念主力净流入为-1.87亿,其中万邦德受到资金热捧,主力净流入1890.07万;拉长时间线来看,该板块近20日主力资金净流入-9.46亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718094828a6b0e67d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718094828a6b0e67d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392","159657"],"gpt_icon":0},{"id":"2551149002","title":"万泰生物:九价HPV疫苗市场定价为499元/支","url":"https://stock-news.laohu8.com/highlight/detail?id=2551149002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551149002?lang=zh_cn&edition=full","pubTime":"2025-07-16 17:27","pubTimestamp":1752658027,"startTime":"0","endTime":"0","summary":"证券之星消息,万泰生物(603392)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问九价HPV疫苗市场定价是多少?什么时候能在市场上看到或打上?万泰生物回复:您好!九价HPV疫苗市场定价为499元/支。公司已按既定计划有序推动批签发,并严格按各省级疫苗管理部门制定的招\\补标以及准入规则推进工作。感谢您对公司的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600028065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","LU1981816686.USD","09633","603392","BK0239","159646","BK1200"],"gpt_icon":0},{"id":"2551414194","title":"万泰生物:公司将全力以赴做好研发和经营工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2551414194","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551414194?lang=zh_cn&edition=full","pubTime":"2025-07-16 17:27","pubTimestamp":1752658020,"startTime":"0","endTime":"0","summary":"有投资者向万泰生物提问, 是否有假,连续创新低?公司回答表示,您好!二级市场股价变动受诸多因素影响,公司将全力以赴做好研发和经营工作,持续加强与市场的沟通,提升自身长期内在价值。公司将按照相关规定履行信息披露义务。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716173918a6ad2949&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716173918a6ad2949&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603392","BK0239"],"gpt_icon":0},{"id":"2551162771","title":"万泰生物:中标北京市红十字血液中心采购项目,中标金额为104.58万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551162771","media":"同壁财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551162771?lang=zh_cn&edition=full","pubTime":"2025-07-15 20:29","pubTimestamp":1752582593,"startTime":"0","endTime":"0","summary":"同壁财经讯,企查查数据显示,根据《[公开]乙型肝炎病毒表面抗原检测试剂盒 中标公告》,北京万泰生物药业股份有限公司于2025年7月15日公告中标北京市红十字血液中心采购项目,中标金额为104.58万元。相关上市公司:万泰生物同壁财经小贴士:万泰生物2024年营业收入为22.45亿元,营业收入增长率为-59.25%,归属母公司净利润为1.06亿元,归属母公司净利润增长率为-91.49%,净资产收益率为0.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715203556a44c704d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715203556a44c704d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2551913778","title":"幽门螺杆菌概念盘中跳水,*ST三圣跌0.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551913778","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551913778?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:17","pubTimestamp":1752545826,"startTime":"0","endTime":"0","summary":"07月15日,幽门螺杆菌概念盘中跳水,截至10点17分,幽门螺杆菌概念整体指数下跌2.09%,报1058.700点。从个股上来看,该概念的成分股中,*ST三圣跌0.20%,万泰生物、东方生物跌幅居前。从资金上来看,截止发稿,幽门螺杆菌概念概念主力净流入为-2.75亿,其中东方海洋受到资金热捧,主力净流入2.90亿;拉长时间线来看,该板块近20日主力资金净流入-64.47亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151017069542d6ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151017069542d6ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688298","002742","603392","BK0132","BK0028","BK0235"],"gpt_icon":0},{"id":"2551130695","title":"生物制品行业盘中跳水,万泰生物跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551130695?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:14","pubTimestamp":1752545650,"startTime":"0","endTime":"0","summary":"07月15日,生物制品行业盘中跳水,截至10点14分,生物制品行业整体指数下跌1.01%,报6341.440点。从个股上来看,该行业的成分股中,万泰生物跌0.14%,通化东宝、康希诺跌幅居前。从资金上来看,截止发稿,生物制品行业主力净流入为-1.47亿,其中安科生物受到资金热捧,主力净流入6409.00万;拉长时间线来看,该板块近20日主力资金净流入-33.28亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071510141097a668cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071510141097a668cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2551149029","title":"每周股票复盘:万泰生物(603392)九价HPV疫苗销售策略及海外拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2551149029","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551149029?lang=zh_cn&edition=full","pubTime":"2025-07-13 06:50","pubTimestamp":1752360619,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘,万泰生物报收于59.5元,较上周的60.65元下跌1.9%。本周关注点机构调研要点:公司九价HPV疫苗通过构建“区域网格化+管理数字化+服务专属化”的新型营销体系推进销售。万泰生物聚焦于体外诊断试剂和预防产品的业务领域,治疗性创新药物属于养生堂集团的业务范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300001225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","603392","BK1200","BK0239","09633","BK1589","LU1981816686.USD"],"gpt_icon":0},{"id":"2551914254","title":"巨头争相入局 竞逐千亿级医美赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2551914254","media":"中国产业经济信...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551914254?lang=zh_cn&edition=full","pubTime":"2025-07-13 00:00","pubTimestamp":1752336000,"startTime":"0","endTime":"0","summary":"近段时间,接连有医药企业、跨界大佬争相“杀入”医美赛道。两项交易总额达34亿元。此次权益变动后,养生堂和杭州久视合计持有锦波生物股份占比超过10%。数据显示,2025年第一季度,锦波生物实现营业收入3.66亿元,同比增长62.51%。同时,华熙生物与巨子生物的玻尿酸与重组胶原蛋白之争,则反映出医美产品快速迭代带来的竞争加剧。针对近期媒体曝光的医美领域乱象,公安部表明将采取有力措施,严厉打击相关违法犯罪活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071307104497a3e1d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071307104497a3e1d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0201","BK0188","688363","603392","BK0187","BK0039","BK0012","688366","BK0097","BK0146","BK0077","600998","BK0196","BK0250","BK0183"],"gpt_icon":0},{"id":"2550761912","title":"万泰生物举办资本市场专项调研会","url":"https://stock-news.laohu8.com/highlight/detail?id=2550761912","media":"新华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550761912?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:16","pubTimestamp":1752131776,"startTime":"0","endTime":"0","summary":"7月8日,北京万泰生物药业股份有限公司在厦门举办《走进万泰生物》资本市场专项调研会,调研会聚焦万泰生物在疫苗和体外诊断领域的优势与商业化能力,解析其国际化战略布局,同时介绍了公司新产品开拓情况以及未来增长潜力。万泰生物将针对不同区域人口特征、消费能力及医疗资源分布,实施差异化销售策略。本次由证券机构联合协办的机构调研会,是万泰生物与资本市场深化沟通、增进了解的重要契机。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710152942a441f8c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710152942a441f8c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2550697199","title":"打破高价壁垒!国产九价HPV疫苗499元上市,98%保护率+两针法(9-17岁)成亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=2550697199","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550697199?lang=zh_cn&edition=full","pubTime":"2025-07-10 13:52","pubTimestamp":1752126739,"startTime":"0","endTime":"0","summary":"7月8日,万泰生物正式公布我国首款国产九价HPV疫苗“馨可宁9”定价为499元/支,约为进口九价HPV疫苗价格的40%。据最新披露的数据,截至2025年5月,仅九价HPV疫苗,万泰生物已完成研发投入约10亿元。按照接种程序,全程三针费用不足1500元,仅为进口九价HPV疫苗的三成多。业内人士指出,国产九价HPV疫苗以更高的质价比进入市场,不仅能提升适龄女性接种意愿,更为构建全民免疫屏障提供了关键支撑,将加速推动消除宫颈癌目标的实现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710135523953d0f1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710135523953d0f1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159646","603392","BK0239"],"gpt_icon":0},{"id":"2550651324","title":"定价499元,大打“低价牌”万泰生物为何没能赢得市场的心?","url":"https://stock-news.laohu8.com/highlight/detail?id=2550651324","media":"大众证券报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550651324?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:19","pubTimestamp":1752067140,"startTime":"0","endTime":"0","summary":"就在一个月前,万泰生物刚刚宣布其旗下首个国产九价HPV疫苗获批上市。截至7月9日收盘,万泰生物股价报60.41元/股,较前一交易日微涨0.80%。不仅如此,如果从公布相关疫苗获批上市的消息起算,万泰生物的股价自6月6日已累计下跌超过22%。其中,四价HPV疫苗批签发47万支,同比下降95.5%;九价HPV疫苗批签发3114万支,同比下降14.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709212033953c3195&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709212033953c3195&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603392"],"gpt_icon":0},{"id":"2550577913","title":"2025年中国疫苗产业格局重构:九价HPV疫苗市场突破与全产业链升级分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2550577913","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550577913?lang=zh_cn&edition=full","pubTime":"2025-07-09 08:22","pubTimestamp":1752020543,"startTime":"0","endTime":"0","summary":"截至2024年底,中国9-45岁女性HPV疫苗首针覆盖率已达27.43%,但相较于欧美国家67%的接种率仍存在显著差距,这一市场缺口正吸引着资本与技术的双重投入。临床数据显示,其自主研发的九价HPV疫苗已启动男性试验,覆盖人群范围扩大至约1.5亿适龄男性群体。目前已有8个国家和地区采用国产二价HPV疫苗作为公共卫生项目,预计九价产品通过省级招补标后将进一步渗透基层市场。通过全产业链协同创新,中国疫苗产业有望在全球健康事业中发挥更重要作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709091945953b857f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709091945953b857f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159646","603392","BK0239"],"gpt_icon":0},{"id":"2549154306","title":"万泰生物:7月8日接受机构调研,东方基金、红土创新基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2549154306","media":"证星公司调研","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549154306?lang=zh_cn&edition=full","pubTime":"2025-07-08 18:01","pubTimestamp":1751968860,"startTime":"0","endTime":"0","summary":"后续若有相关安排,公司将严格按照相关法律法规的要求,及时履行信息披露义务。万泰生物聚焦于体外诊断试剂和预防产品的业务领域,治疗性创新药物属于养生堂集团的业务范围。万泰生物主营业务:体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。该股最近90天内共有2家机构给出评级,买入评级1家,增持评级1家;过去90天内机构目标均价为68.33。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708180501953ab0df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708180501953ab0df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603392","BK0239"],"gpt_icon":0},{"id":"2549543064","title":"国产九价HPV疫苗与进口效果相当,最终定价仅499元,不到进口一半","url":"https://stock-news.laohu8.com/highlight/detail?id=2549543064","media":"新华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549543064?lang=zh_cn&edition=full","pubTime":"2025-07-08 17:53","pubTimestamp":1751968380,"startTime":"0","endTime":"0","summary":"2007年,夏宁邵团队正式启动了九价HPV疫苗的研发。截至目前,我国3亿9至45岁女性中,未接种HPV疫苗的比例高达70%至80%。据最新披露的数据,截至2025年5月,仅九价HPV疫苗,已完成研发投入约10亿元。国产HPV疫苗研发之路虽然崎岖,但步履坚实。业内人士指出,国产九价HPV疫苗以更高的质价比进入市场,不仅能提升适龄女性接种意愿,更为构建全民免疫屏障提供了关键支撑,能够加速推动消除宫颈癌目标的实现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708175624953aae39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708175624953aae39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603392","159646","BK0239"],"gpt_icon":0},{"id":"2549115085","title":"万泰生物:公司正在全力推进九价HPV疫苗WHO PQ认证进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2549115085","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549115085?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:28","pubTimestamp":1751963300,"startTime":"0","endTime":"0","summary":"蓝鲸新闻7月8日电,万泰生物(603392.SH)发布投资者关系活动记录表公告称,在九价HPV疫苗获批后,公司已按既定计划有序推动全国各省招补标工作。公司正在全力推进九价HPV疫苗WHO PQ认证进程,依托公司二价HPV疫苗已取得的国际化成果(已在海外获得20余个国家的市场准入,纳入8个国家的免疫规划项目)及构建的全球化网络,公司有信心将以更快的速度推动九价HPV疫苗的海外准入及拓展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163016979e167c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708163016979e167c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159646","603392","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753328660924,"stockEarnings":[{"period":"1week","weight":0.0072},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0762},{"period":"6month","weight":-0.1246},{"period":"1year","weight":-0.1236},{"period":"ytd","weight":-0.1494}],"compareEarnings":[{"period":"1week","weight":0.0224},{"period":"1month","weight":0.0594},{"period":"3month","weight":0.0864},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.2288},{"period":"ytd","weight":0.0688}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30955人(较上一季度增加2.21%)","perCapita":"40869股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126512万元","survey":" 北京万泰生物药业股份有限公司的主营业务是体外诊断试剂、自动化检测设备、疫苗研发生产及销售。公司的主要产品是公司业务不断向多元化拓展,目前已形成了包括原料、质控品、诊断设备、免疫、生化、分子、疫苗在内的全产业链医防融合产品布局,横跨七个不同的技术平台。截至报告期末,体外诊断领域,公司拥有有效专利167项,其中发明专利117项,实用新型专利43项,外观设计7项。报告期内,公司申请专利52项,其中发明专利39项;获得授权专利26项,其中国内授权21项,国际授权5项。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}